Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in Head and Neck Squamous Cell Carcinoma
NCT06385080Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Dec 2032
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, open-label trial of amivantamab in head and neck squamous cell carcinoma (HNSCC) (7 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective Response Rate, Number of Participants With Dose-limiting Toxicities up to 21 days and 2 more. Started Apr 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06385080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385080.